Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma

Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of Lymphoid Malignancies. London: Martin Dunitz Ltd; 2001. p. 153-67.Search in Google Scholar

Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-43.10.1038/sj.onc.120834915789036Search in Google Scholar

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.10.1182/blood.V84.8.2457.2457Search in Google Scholar

Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann of Oncol 2003; 14: 520-35.10.1093/annonc/mdg17512649096Search in Google Scholar

Maloney DG. Mechanisms of action of rituximab. Anticancer Drugs 2001; 12 Suppl 2: S1-S4.Search in Google Scholar

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.10.1200/JCO.1999.17.4.124410561185Search in Google Scholar

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.10.1038/sj.onc.120693914576843Search in Google Scholar

Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L, et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother 2005; 54: 273-86.10.1007/s00262-004-0599-415449038Search in Google Scholar

Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. BMC Cancer 2005; 5: 103.10.1186/1471-2407-5-103120886216109167Search in Google Scholar

Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264-76.10.1158/0008-5472.264.65.1Search in Google Scholar

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.10.1038/7470410742152Search in Google Scholar

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.10.1182/blood.V83.2.435.435Search in Google Scholar

Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis. Blood 2000; 95: 3900-8.10.1182/blood.V95.12.3900.012k14_3900_3908Search in Google Scholar

Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-24.10.1182/blood.V94.7.2217.419k02_2217_2224Search in Google Scholar

Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.10.1056/NEJM1993093032914028141877Search in Google Scholar